TargetMol

Biofor 389

Product Code:
 
TAR-T26820
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T26820-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26820-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T26820-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Biofor 389 is a potent, orally active, antiarthritic and analgesic agent.
CAS:
127245-22-1
Formula:
C20H29NO3
Molecular Weight:
331.456
Purity:
0.98
SMILES:
CN1OCCC(=C/c2cc(c(O)c(c2)C(C)(C)C)C(C)(C)C)C1=O

References

1. Veerhuis R, Hoozemans JJ, Janssen I, Boshuizen RS, Langeveld JP, Eikelenboom P. Adult human microglia secrete cytokines when exposed to neurotoxic prion protein peptide: no intermediary role for prostaglandin E2. Brain Res. 2002 Jan 25;925(2):195-203. PubMed PMID: 11792368. 2. Blom MA, van Twillert MG, de Vries SC, Engels F, Finch CE, Veerhuis R, Eikelenboom P. NSAIDS inhibit the IL-1 beta-induced IL-6 release from human post-mortem astrocytes: the involvement of prostaglandin E2. Brain Res. 1997 Nov 28;777(1-2):210-8. PubMed PMID: 9449430. 3. Wong S, Lee SJ, Frierson MR 3rd, Proch J, Miskowski TA, Rigby BS, Schmolka SJ, Naismith RW, Kreutzer DC, Lindquist R. Antiarthritic profile of BF-389--a novel anti-inflammatory agent with low ulcerogenic liability. Agents Actions. 1992 Sep;37(1-2):90-8. PubMed PMID: 1456184. 4. Bendele AM, Ruterbories KJ, Spaethe SM, Benslay DN, Lindstrom TD, Lee SJ, Naismith RW. Correlation of anti-inflammatory activity with peak tissue rather than peak plasma levels of BF389. J Pharmacol Exp Ther. 1992 Mar;260(3):1194-8. PubMed PMID: 1545387.